Skip to main content
. Author manuscript; available in PMC: 2017 Jan 4.
Published in final edited form as: Nat Med. 2016 Jul 4;22(8):851–860. doi: 10.1038/nm.4123

Figure 3.

Figure 3

FAK inhibitor suppresses tumor progression and metastasis. (a) Tumor grading analysis on pancreas tissue from end-stage vehicle- and FAKi-treated KPC mice for each disease stage (left, n = 16–17 mice/group) and percentage of high-grade PDAC in total PDAC area (right, n = 5 mice/group). (b) Immunohistochemistry analysis and quantification of YFP+ invasive tumor cells in PDAC tissue from KPC-Y mice treated for 1 month with vehicle or FAKi; scale bars, 200 μm for left panel (magnified field, 100 μm) and 260 μm for right panel. Arrowheads indicate single invading tumor cells (n = 5 mice/group). (c) Flow cytometry analysis of % ALDHBright and % CD24Hi CD44Hi tumor cells in KI orthotopic tumors treated for 10 days with vehicle or FAKi (n = 6–7 mice/group). (d) Histology analysis for frequency of liver metastases from KPC mice treated with vehicle or FAKi; scale bar, 200 μm. Error bars, mean ± s.e.m.; * indicates P < 0.05 by Student’s t-test (a-c), or Fisher’s exact test (d).